Deutivacaftor is an altered form of the potentiator ivacaftor (Kalydeco®). Potentiators are drugs that facilitate the opening of the chloride channel on the cell surface to allow chloride and sodium (salt) to move in and out of the cell. Deutivacaftor, or deuterated ivacaftor, may be more stable in the body than regular ivacaftor, which would allow it to be taken once a day.

Status

A phase 2 study was conducted to test the safety and effectiveness of deutivacaftor in adults with CF who have a CFTR gating mutation. Deutivacaftor is currently being tested in combination with two correctors, vanzacaftor and tezacaftor, to form a new triple-combination modulator therapy.

No further studies of deutivacaftor alone are planned at this time.

Sponsor

This program was sponsored by Vertex Pharmaceuticals and conducted within the Therapeutics Development Network.